contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-1002-netcompany-scandinavian-medical-solutions-og-ascelia-pharma-ab0

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Equities

Michael Friis

CEO, Sweden

Claus Thestrup

Head of Research, Stables

Rasmus Køjborg

Netcompany Group is an IT company. The company specializes in consulting services and business-critical IT solutions, including internal systems development, big data management, mobile apps, analysis services, and E-commerce solutions. The customers can be found in several sectors, including finance, industry, authorities, and institutes. Netcompany was founded in 2000 and has its headquarters in Copenhagen.

Netcompany Group

Scandinavian Medical Solutions is a Danish-based trading company specialized in purchase and resale of used diagnostic imaging equipment such as CT scanners and MR scanners of high quality. Scandinavian Medical Solutions is specialized in offering flexible solutions for customers with specific demands, which is often a better and cheaper alternative to a new and more expensive produced OEM-equipment.

Scandinavian Medical Solutions was founded in 2018, and the company has been listed at Nasdaq First North in Denmark since November 2021.

kan også se jeg ramte min forudsigelse ret godt   Kun 0,5 mio fra begge intervaller

guidance for 2022/2023 i starten af året  Omsætning: 125-140 mio  EBITDA: 15-17 mio 9 MARTS  Omsætning: 140-155 mio  EBITDA: 17-19 mio 15  MAJ  Omsætning: 150-165 mio  EBITDA: 18,5-20,5 mio Noget af en udvikling bare i år - de kom vidst også med 4 opjustering i 2022 hvis jeg husker rigtigt:)

Nu er der kommet 2 opjustering efter sidste skriv. Ordrene flyver ind pt. (især rental). Bliver et spændende år for sms!

Med lavere fragtrater + en stor stigning i lejekontrakter, forventer jeg en opjustering i EBITDA (Omkring 18-20 mio). En lønsom virksomhed, med høj vækst til omkring 7 EV/EBIT 2023e - ligner 2023 bliver et rigtig postivt år for SMS

Scandinavian Medical Solutions meddelte i går markedet, at virksomheden har solgt tre mobile billeddiagnostiske løsninger til en europæisk kunde, der skal øge scanningskapaciteten på flere lokationer. Værdien er i intervallet DKK 2 mio. og under DKK 3,5 mio. Levering og risikoovergang skete i begyndelsen af 2023 og ændrer ikke på selskabets guidance for regnskabsåret 2022/2023 (1. oktober 2022 til 30. september 2023), der er en omsætning i niveauet DKK 125-140 mio. og EBITDA i niveauet DKK 15-17 mio. Scandinavian Medical Solutions’ regnskab for H1 2022/2023 ventes at blive aflagt den 16. maj 2023. Hvad er jeres forventninger til regnskabet?

I tirsdag afholdte Scandinavian Medical Solutions deres præsentation af årsrapporten for 2021/2022. Det var et godt event, hvor CEO, Jens Krohn, dykkede ned badved de finansielle resultater og snakkede om hans forventninger for det kommende år

Scandinavian Medical Solutions

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ikke bliver opfyldt og har en klar udviklings- og markedsvej. Ascelia Pharma har to pipeline-produkter, nemlig Orviglance og Oncoral. Orviglance (tidligere Mangoral) er selskabets hovedprodukt. Orviglance er i et fase 3-studie og estimeres at blive godkendt i 2023. Orviglance er et nyt kontrastmiddel til MR-scanning, udviklet til at forbedre påvisning og visualisering af leverlæsioner (inklusiv lever metastaser – og primære tumorer) hos patienter med nedsat nyrefunktion. Derudover har selskabet et fase-2 studie produkt i Oncoral som estimeres at have en færdiggørelsesdato i 2024. Oncoral er en tablet som indtages dagligt med en etableret potent anti-tumor-effekt – selv i svært behandlende kræftformer med potentiale for at tilbyde bedre patientresultater. Oncoral øger patientsikkerheden i og med patienten får en mildere dosis dagligt i form af en tablet, fremfor løbende intravenøse højdosis infusioner på hospitalet. English:  Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments.  They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance (Former working name Mangoral) is their main product which is a phase 3 study with an estimated completion date in June 2022. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma

Dagens aktienyheder 10/2-2025: Netcompany, Scandinavian Medical Solutions og Ascelia Pharma AB.

Dagens aktienyheder 10/02: Netcompany, Scandinavian Medical Solutions og Ascelia Pharma AB. Netcompany meddeler her til morgen, at selskabet har indg&#xe5;et en aftale med SDC, og majoriteten af SDC&#x2019;s aktion&#xe6;rer om at danne et nyt selskab imellem de to parter, og med Netcompany som eneejer. Transaktionen v&#xe6;rdians&#xe6;tter SDC til DKK 1 mia., som Netcompany betaler til SDC&#x2019;s nuv&#xe6;rende aktion&#xe6;rer. Aftalen ventes at falde endelig p&#xe5; plads i midten af 2025 n&#xe5;r en r&#xe6;kke regulatoriske og &#xf8;vrige forhold er afklaret. SDC havde ved udgangen af 2024 omkring 980 fuldtidsansatte fordelt p&#xe5; 3 lande, og havde i regnskabs&#xe5;ret 2023 en oms&#xe6;tning p&#xe5; DKK 1.837 mio. og EBITDA p&#xe5; DKK 286,8 mio. Det svarer til en EV/EBITDA multipel p&#xe5; 3,5x uden indregning af eventuelle synergier. Til sammenligning handler Netcompany selv p&#xe5; en 2025 EV/EBITDA multipel p&#xe5; ca. 12x. Netcompany fastholder sin guidance for 2025, og venter at genoptage sit aktietilbagek&#xf8;bsprogram. L&#xe6;s hele meddelelsen fra Netcompany her: <a href="https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=7341858&amp;lang=en-GB&amp;companycode=dc-nctop&amp;v=redesign" target="_self">https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=7341858&amp;lang=en-GB&amp;companycode=dc-nctop&amp;v=redesign</a> Scandinavian Medical Solutions annoncerede i fredags deres st&#xf8;rste ordre i dette regnskabs&#xe5;r inden for forretningsomr&#xe5;det Aftersales &amp; Parts til en loyal reservedelskunde. Salget har en v&#xe6;rdi, der ligger inden for intervallet DKK 5 mio. til DKK 8,5 mio. Komponenterne er overleveret i uge 6. Udover st&#xf8;rrelsen af salget er det ogs&#xe5; v&#xe6;sentligt, da det understreger potentialet inden for forretningsomr&#xe5;det Aftersales &amp; Parts. L&#xe6;s mere her om ordren og ordreindgang &#xe5;r til dato sammenlignet med sidste &#xe5;r. <a href="https://www.inderes.dk/analyst-comments/scandinavian-medical-solutions-stor-ordre-annonceret-inden-for-aftersales-and-parts" target="_self">https://www.inderes.dk/analyst-comments/scandinavian-medical-solutions-stor-ordre-annonceret-inden-for-aftersales-and-parts</a> Ascelia Pharma AB - Wrap up from interview with Deputy CEO and CFO Julie W. Brogren Friday 7th February: <a href="https://www.inderes.dk/analyst-comments/ascelia-pharma-wrap-up-from-interview-deputy-ceo-and-cfo-julie-waras-brogren" target="_self">https://www.inderes.dk/analyst-comments/ascelia-pharma-wrap-up-from-interview-deputy-ceo-and-cfo-julie-waras-brogren</a> Disclaimer:&#xa0;HCA - HC Andersen Capital&#xa0;modtager betaling fra selskaberne for en Digital IR aftale. Rasmus K&#xf8;jborg, CFA - 10/02-2025 kl. 9:05

Dagens aktienyheder 10/02: Netcompany, Scandinavian Medical Solutions og Ascelia Pharma AB.0

Privacy preferences